19.30 0.00 (0.00%)
After hours: 4:00PM EST
|Bid||18.75 x 800|
|Ask||19.28 x 800|
|Day's Range||18.87 - 19.82|
|52 Week Range||13.90 - 35.82|
|Beta (5Y Monthly)||1.52|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 5, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||32.75|
Biotech investment is fraught with risk. Most biotech stocks are at the mercy of binary events, which serve as make-or-break catalysts. These binary events , however, provide an opportunity for making ...
Akcea Therapeutics, Inc. (AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., announced today that Alex Howarth has joined the company as chief operating officer. In this role, Mr. Howarth will oversee a broad range of operational areas including corporate strategy, business development, management of stakeholder alliances, legal and compliance, as well as product supply chain.
Akcea Therapeutics, Inc. (AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (IONS), today announced initiation of the NEURO-TTRansform Phase 3 clinical trial for AKCEA-TTR-LRx in patients with polyneuropathy caused by h856ereditary TTR amyloidosis, or hATTR amyloidosis. AKCEA-TTR-LRx is an antisense drug developed using Ionis’ proprietary LIgand Conjugated Antisense (LICA) technology platform and is designed to inhibit production of TTR.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 19) 89bio Inc (NASDAQ: ETNB ) (IPOed Nov. 11) Allergan ...
Akcea Therapeutics, Inc. (AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (IONS), today announced the closing of the exclusive licensing agreement with Pfizer Inc. (PFE) for AKCEA-ANGPTL3-LRx following expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act). AKCEA-ANGPTL3-LRx is an investigational antisense therapy discovered by Ionis and being developed to treat patients with certain cardiovascular and metabolic diseases. As previously announced, under terms of the agreement Akcea and Ionis will receive a $250 million upfront license fee, which will be split equally between the two companies.
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Akcea Therapeutics, Inc., an affiliate of Ionis Pharmaceuticals, Inc. (IONS), is a biopharmaceutical company focused on developing and commercializing drugs to treat patients with serious and rare diseases. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs.
Overall, the stock markets have been gaining in recent months. October saw a 2% bump for the general S&P 500 index, as did the Dow Jones average. But not all market segments are created equal, and some brought stronger returns for investors than others. The biotech industry, for example, had a particularly good month in the stock markets.The Biotech ETF, a sub-index of the NASDAQ that tracks the performance of stocks in the biotechnology and pharmaceutical sectors, rose 8% last month, four times the broader market’s average. The gains were led by the big names in the sector, but smaller stocks were also showing strength. Analysts from Needham, one of Wall Street’s top financial research firms, have picked out three small-cap biotechs that are showing a combination of recent gains and fantastic upside.Akcea Therapeutics (AKCA)A publicly traded company since July 2017, Akcea focuses on treatments for rare, serious diseases. The company’s main approved product, Tegsedi, treats “polyneuropathy caused by hereditary transthyretin-mediated amyloidosis” in adults. The drug is available in the US, Canada, and the EU. Waylivra, for the treatment of familial chylomicronemia syndrome, has been approved in the EU.Akcea has an active research pipeline with new drugs in all stages of testing, from pre-clinical to up to the FDA registration process. Most of Akcea’s products are for the treatment of cardiometabolic lipid disorders.In the Q3 earnings report, Akcea beat the EPS forecast by 38%, showing a net loss of 34 cents per share against the forecast 55 cents. In addition to beating the estimate, the quarterly EPS also showed a strong improvement from the year-ago quarterly loss of 58 cents. During the month of October, AKCA gained 24%, triple the overall biotech sector gains.Needham’s 4-star analyst Chad Messer writes of AKCA shares, “AKCA shares could go higher if the company can establish a pathway to approval for Waylivra with the FDA in FCS, if Waylivra reports positive data in FPL, or AKCEA-APOCIII-LRx, AKCEA-APO(a)-LRx, or AKECA-ANGPTL3-LRx report positive Phase II data. AKCA shares could also be driven higher by higher than expected sales for Tegsedi in FAP-ATTR.” Messer gives AKCA stock a $45 price target, implying a 127% upside and reflecting his optimism on the company’s path forward in the regulatory processes.With 3 recent Buy ratings, and only 1 Hold, AKCA has a Strong Buy from the analyst consensus. Shares sell for a modest $19.53, and the $40.50 average price target suggests an upside potential of 104%. (See Akcea stock analysis on TipRanks) Dermira (DERM)As its name suggests, Dermira is a pharmaceutical company focusing on dermatalogical issues, that is, on the treatment of chronic skin conditions. It’s easy to overlook, but the skin is the largest organ of the human body, and fills a wide range of rolls from keeping our insides in while keeping the outside out, to helping us regulate our body temperature.Dermira’s first approved products, Qbrexza, is a medicated cloth designed to treat hyperhidrosis – extreme sweating – in the armpits. The company also has Lebrikizumab, a treatment for atopic dermatitis, has just entered Phase 3 testing. Other projects are still in the pre-clinical testing phases.Like AKCA above, Dermira showed a strong Q3 despite operating at a net loss. The net loss per earning was $1.06, a 24% improvement from the expected EPS loss of $1.40. This marked the third time in the past year that DERM has beating the earnings forecast. The positive earnings news came after the stock had gained 15% in October.In a November 6 report on DERM, Needham analyst Serge Belanger focused on the company’s two main pharmaceutical products. He wrote, “The bulk of the recent DERM news flow revolved around lebrikizumab and its ph 3 program that got underway in mid-Oct. The 3Q19 financials and update mostly centered around the launch progression of Qbrexza, which generated sales of $10.2MM, surpassing Street expectations… Qbrexza is on pace to meet the low-$30MM 2019 sales guidance.”Belanger maintained his firm’s Buy rating on this stock, and gave it a $20 price target. His target implies a 185% potential to the upside.DERM gets a Strong Buy analyst consensus rating, with 3 Buys set in just the past week. The stock is a bargain price, at $7, but the potential of its new drugs and its research pipeline give it a high average price target of $19, and an impressively robust upside potential of 171%. (See Dermira stock analysis on TipRanks) G1 Therapeutics (GTHX)Once an almost certainly deadly, new treatments in recent years have brought hope to many cancer patients. G1 has a series of drugs in testing for small cell lung cancer, breast cancer, and colorectal cancer. The lung cancer treatments are in late stage testing and scheduled for regulatory submission in 2020. Also in 2020, the breast cancer and colorectal cancer treatments are scheduled to start trials.G1 shares were mostly flat in October, reflecting the differences between this company and the two listed above: where its peers above showed strong positive surprises in Q3 earnings, G1’s EPS loss was in line with estimates at 86 cents. Without any strong earnings surprise, and without any products post-approval, G1 did not shake up the expectations.Where this stock shines, however, is in long-term performance and forward potential. GTHX is up 20% year-to-date, a reflection of the hopes pinned on the latent possibilities of new cancer treatments. Chad Messer, quoted above, touches on this in his report on GTHX when he writes, “G1 remains on track to file a trilaciclib NDA and MAA in 2020 for myelopreservation in small cell lung cancer (SCLC). The next driver for GTHX is updated results from the Phase Ib study of lerociclib…” Messer’s price target of $74 suggests an upside of 223% to the stock – significantly higher than that implied for the stocks above.Messer is not the only analyst impressed by GTHX’s prospects in the cancer treatment research field. The stock has Buy ratings from 6 analysts recently, making its consensus rating a unanimous Strong Buy. Shares are trading for $22.82, and the average stock-price forecast of $65.50 indicates an upside potential of 169%. (See GTHX stock analysis on TipRanks)
Akcea Therapeutics (AKCA) delivered earnings and revenue surprises of 38.18% and 39.35%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Reported Third Quarter 2019 Global Net Product Revenues of $12 Million WAYLIVRA® (volanesorsen) launched in the E.U. Entered into a worldwide licensing agreement with Pfizer,.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 4) Agile Therapeutics Inc (NASDAQ: AGRX )(follow-on rally ...
Akcea Therapeutics, Inc. (AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc. (IONS), today recognizes Familial Chylomicronemia Syndrome (FCS) Awareness Day. FCS Awareness Day is a global observance held each year on the first Friday in November to build broader awareness of the challenges associated with this devastating, ultra-rare disease and the critical need for treatment. Along with members of the FCS community around the world, Akcea celebrates the significant progress made over the past year, including the EU approval of WAYLIVRA, the only treatment approved for FCS, as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk for pancreatitis.
Akcea Therapeutics (AKCA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Akcea Therapeutics (AKCA) has been upgraded to a Zacks Rank 1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Akcea Therapeutics, Inc. (AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., announced today that the company has promoted Kyle Jenne to chief commercial officer. Having had a key role in building our commercial organization over the last two years, Kyle also is very familiar with the hATTR and FCS communities and is committed to both the clinician and patient communities we serve,” said Damien McDevitt, Ph.D., Akcea’s interim chief executive officer. Mr. Jenne joined Akcea in May 2017 as the U.S. commercial head and built the company’s first sales force and executed the launch of TEGSEDI in the U.S. With two decades of commercial experience in the biopharmaceutical industry, he has led the build-out and leadership of organizations in many therapeutic areas, including cardiovascular and lipid-driven diseases, rare diseases and oncology.
Akcea Therapeutics, Inc. (AKCA), an affiliate of Ionis Pharmaceuticals, Inc., announced today that it will host a live webcast on Tuesday, November 5th at 4:30 p.m. Eastern Time to discuss its third quarter 2019 financial results and report on pipeline and business progress. Akcea Therapeutics, Inc., an affiliate of Ionis Pharmaceuticals, Inc. (IONS), is a biopharmaceutical company focused on developing and commercializing drugs to treat patients with serious and rare diseases. All six drugs were discovered by Ionis, a leader in antisense therapeutics, and are based on Ionis’ proprietary antisense technology.
The Insider Monkey team has completed processing the quarterly 13F filings for the June quarter submitted by the hedge funds and other money managers included in our extensive database. Most hedge fund investors experienced strong gains on the back of a strong market performance, which certainly propelled them to adjust their equity holdings so as […]
Quest Diagnostics (DGX) is likely to have retained its two-pronged agenda to accelerate growth and drive operational excellence in the third quarter.
The recent full-market launch of the HemoSphere platform with the FloTrac System and Acumen Hypotension Predictive Index should reflect in Edwards Lifesciences' (EW) third-quarter results.
Abbott (ABT) has been growing popular with developments in its flagship, market leading device for the treatment of mitral regurgitation, MitraClip.
Abbott (ABT) is steadily gaining prominence for developments in its flagship, sensor-based continuous glucose monitoring (CGM) system of FreeStyle Libre.
Shares of Akcea Therapeutics rocketed in higher-than-average volume on Monday after the Ionis Pharmaceuticals affiliate announced a licensing deal with Dow Jones component Pfizer.